Brian J. Schiro

Brian J. Schiro

Auto-generated profile, based on publicly available information

Brian J. Schiro

Department of Interventional Radiology, Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, USA; Florida International University Herbert Wertheim College of Medicine

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
JMJohn M. Moriarty
John M. Moriarty
SDSuhail Y. Dohad
Suhail Y. Dohad
BSBrian J. Schiro
Brian J. Schiro
HTHouman Tamaddon
Houman Tamaddon
RHRobert E. Heithaus
Robert E. Heithaus
IWIdo Weinberg
Ido Weinberg
To report 90-day results from the first interim analysis of the STRIKE-PE study, which is evaluating safety, effectiveness, and functional and quality of life (QoL) outcomes of Computer Assisted Vacuum Thrombectomy (CAVT) with the Indigo Aspiration System for the treatment of acute pulmonary embolism (PE). STRIKE-PE is a prospective, international, multicenter study that will enroll 600 adult patients with acute PE of ≤14 days and a right ventricle/left ventricle (RV/LV) ratio of ≥0.9 who receive first-line endovascular treatment with CAVT. Primary endpoints are change in RV/LV ratio and incidence of composite major adverse events (MAEs) within 48 hours. Secondary endpoints include functional and QoL assessments. The first 150 consecutive patients were treated with Lightning 12 CAVT. Mean age was 61.3 years, 54.7% were men, 94.7% presented with intermediate-risk PE, and 5.3% presented with high-risk PE. Median thrombectomy and procedure times were 33.5 minutes and 70 minutes, respectively, resulting in a mean reduction in systolic pulmonary artery pressure of 16.3% (P < .001). Mean RV/LV ratio decreased from 1.39 before thrombectomy to 1.01 at 48 hours, a 25.7% reduction (P < .001). Four patients (2.7%) experienced a composite MAE within 48 hours. At 90-day follow-up, patients exhibited statistically significant improvements in the Borg dyspnea scale and QoL measures, and the NYHA class distribution returned to that reported before the index PE. These interim results demonstrate a rapid reduction in RV/LV ratio, achieved with a fast thrombectomy time while maintaining safety. This is accompanied by improvements in 90-day functional and QoL outcomes.

30 August 2024 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Open access
GNGovindarajan Narayanan
Govindarajan Narayanan
NGNicole T. Gentile
Nicole T. Gentile
JEJonathan Eyshi
Jonathan Eyshi
BSBrian J. Schiro
Brian J. Schiro
RGRipal T Gandhi
Ripal T Gandhi
MDMadelon Dijkstra
Madelon Dijkstra
Purpose: To evaluate the safety, effectiveness, and oncological outcomes of irreversible electroporation (IRE) of unresectable colorectal liver metastases (CRLMs) close to critical structures. Materials and Methods: This is a single-center, institutional review board (IRB)-approved, retrospective analysis of patients who underwent percutaneous computed tomography (CT)-guided IRE of CRLM. Between August 2018 and October 2023, 26 patients had 46 tumors treated with percutaneous IRE in 30 ablation sessions. Primary end points were tumor response and local progression-free survival analyzed using Kaplan-Meier survival curves. Secondary end points were overall survival (OS), distant progression-free survival (DPFS) analyzed using Kaplan-Meier survival curves, adverse events rated according to the Common Terminology Criteria for Adverse Events (CTCAE), and length of hospital stay. Results: All tumors were close to critical structures, including the portal and hepatic veins, inferior vena cava, bile ducts, and gallbladder. All patients received preprocedural systemic therapy (median 10 cycles). Median length of hospital stay was 1 night. Adverse events occurred in 7 (23%) of 30 procedures, with four Grade 1 and two Grade 2 adverse events, including pleural effusions (n = 2), ileus (n = 1), small hematoma (n = 1), and pneumothorax (n = 2) requiring chest tube placements. Following IRE, the 1- and 2-year local tumor progression-free survival rates were 55.0% and 51.3%. The median DPFS was 3.5 months, with 1- and 2-year DPFS rates of 23.3% and 9.7%. Six patients (23.1%) died during follow-up, with a median OS of 40.4 months. The 1-and 2-year OS rates were 90.9% and 83.9%. Conclusions: IRE is a safe and viable option in the treatment of unresectable CRLMs in locations close to critical structures, but carries a risk of local recurrence.

6 August 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AKAdis Kukuljac
Adis Kukuljac
AAAaron Abrishami
Aaron Abrishami
PSParnavi Singh
Parnavi Singh
JBJoshua M. Baker
Joshua M. Baker
SKSyed Kazmi
Syed Kazmi
BSBrian J. Schiro
Brian J. Schiro

5 May 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
NGNathan C. Gilmore
Nathan C. Gilmore
CDCristobal Ducaud
Cristobal Ducaud
BSBrian Schiro
Brian Schiro
MGMehrdad Ghoreishi
Mehrdad Ghoreishi

19 January 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PSParnavi Singh
Parnavi Singh
ITIbrahim Thein
Ibrahim Thein
AAAaron Abrishami
Aaron Abrishami
JBJoshua M. Baker
Joshua M. Baker
CAChikamuche Thaddeus Anyanwu
Chikamuche Thaddeus Anyanwu
BSBrian J. Schiro
Brian J. Schiro

17 November 2026 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
JBJoshua M. Baker
Joshua M. Baker
PSParnavi Singh
Parnavi Singh
SFSergio J. Torralbas Fitz
Sergio J. Torralbas Fitz
EPEmery Perrin
Emery Perrin
SLSebastian Leal
Sebastian Leal
BSBrian J. Schiro
Brian J. Schiro